Hanmi Pharm Balance Sheet Health
Financial Health criteria checks 6/6
Hanmi Pharm has a total shareholder equity of ₩1,219.5B and total debt of ₩509.5B, which brings its debt-to-equity ratio to 41.8%. Its total assets and total liabilities are ₩1,975.7B and ₩756.2B respectively. Hanmi Pharm's EBIT is ₩266.6B making its interest coverage ratio 11.5. It has cash and short-term investments of ₩246.9B.
Key information
41.8%
Debt to equity ratio
₩509.46b
Debt
| Interest coverage ratio | 11.5x |
| Cash | ₩246.89b |
| Equity | ₩1.22t |
| Total liabilities | ₩756.21b |
| Total assets | ₩1.98t |
Recent financial health updates
Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly
Jun 11
Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky
Feb 16
Recent updates
Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 16Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now
Jul 31Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?
Jul 16Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly
Jun 11A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
May 08Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up
Apr 22Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)
Mar 15Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky
Feb 16What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?
Jan 17Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years
Dec 22Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate
Nov 24Financial Position Analysis
Short Term Liabilities: A128940's short term assets (₩739.3B) exceed its short term liabilities (₩678.1B).
Long Term Liabilities: A128940's short term assets (₩739.3B) exceed its long term liabilities (₩78.1B).
Debt to Equity History and Analysis
Debt Level: A128940's net debt to equity ratio (21.5%) is considered satisfactory.
Reducing Debt: A128940's debt to equity ratio has reduced from 100.2% to 41.8% over the past 5 years.
Debt Coverage: A128940's debt is well covered by operating cash flow (49.7%).
Interest Coverage: A128940's interest payments on its debt are well covered by EBIT (11.5x coverage).